Search

Your search keyword '"Aranow C"' showing total 326 results

Search Constraints

Start Over You searched for: Author "Aranow C" Remove constraint Author: "Aranow C"
326 results on '"Aranow C"'

Search Results

1. AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY

2. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort

3. S15.2 Severe non-adherence to hydroxychloroquine is associated with flares, early damage, and mortality in systemic lupus erythematosus: data from 660 patients from the slicc inception cohort

4. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

5. Efficacité et tolérance du traitement séquentiel belimumab (BEL) sous-cutané et rituximab (RTX) chez des patients atteints de lupus systémique (LS) : étude BLISS-BELIEVE de phase 3, randomisée, contrôlée versus placebo

6. OP0281 PHARMACODYNAMIC EFFECT OF SEQUENTIAL BELIMUMAB (BEL) AND RITUXIMAB (RTX) THERAPY IN PATIENTS (PTS) WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): THE PHASE 3, RANDOMISED, PLACEBO-CONTROLLED BLISS-BELIEVE STUDY

7. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force.

8. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

9. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force

10. DORIS definition of remission in SLE: final recommendations from an international task force

11. OP0296 THE 2021 DORIS DEFINITION OF REMISSION IN SLE – FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE

12. OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT

13. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force.

14. 2021 DORIS definition of remission in SLE: final recommendations from an international task force

15. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus

16. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus

18. OP0167 SUCCESSFUL WITHDRAWAL OF MYCOPHENOLATE MOFETIL IN QUIESCENT SLE: RESULTS FROM A RANDOMIZED TRIAL

19. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

20. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study

22. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study

23. Mortality in Systemic Lupus Erythematosus

24. Race/Ethnicity and Cancer Occurrence in Systemic Lupus Erythematosus

25. An International Cohort Study of Cancer in Systemic Lupus Erythematosus

26. Lymphoma risk in systemic lupus: effects of treatment versus disease activity

27. Reply

28. Reply

31. OP0251 Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extension

32. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

33. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS)

34. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients

35. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

36. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS).

37. Breast cancer in systemic lupus

38. Anti-C1q antibodies in systemic lupus erythematosus

39. Breast cancer in systemic lupus

40. OP0186 Immune Complex Bound U1 and Y1 RNA Correlates with Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Sysytemic Lupus Erythematosus Patients

42. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus

43. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus

44. Remission in SLE: Consensus findings from a large international panel on Definitions Of Remission in SLE (DORIS).

45. Anti-C1q antibodies in systemic lupus erythematosus

47. OP0092 Remission in Sle: Consensus Findings from a Large International Panel on Definitions of Remission in SLE (DORIS)

49. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

50. Autoantibodies and Neuropsychiatric events at diagnosis of SLE: Results from an international inception cohort study

Catalog

Books, media, physical & digital resources